Sun Pharma Advanced Research Company Limited has informed the Exchange regarding allotment of 3,85,10,000 Warrants pursuant to Preferential Issue at its meeting held on May 19, 2026
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma Advanced Research Company (SPARC) allotted 3,85,10,000 convertible warrants to Shanghvi Finance Private Limited at INR 155.80 per warrant on preferential basis. The company received INR 149.99 crore (25% of the total issue price) as upfront payment, with the balance payable upon conversion. Each warrant is convertible into one fully paid-up equity share of face value INR 1. The paid-up capital remains unchanged for now but will increase upon warrant conversion. The warrants were allotted following board approval (January 14, 2026), shareholder approval (February 9, 2026), and in-principle exchange approvals (May 8, 2026).
SPARC receives INR 150 crore in immediate capital while delaying full equity dilution until warrant conversion. Shanghvi Finance, a promoter-group entity, increases its potential stake, which could be positive for the company's funding position.